Glyxambi (Empagliflozin / Linagliptin)

Prescription Glyxambi is a combination of empagliflozin (Jardiance) and linagliptin (Tradjenta) to treat adults with type 2 diabetes along with know CV (cardiovascular) disease.  Glyxambi is an appropriate medicine for people would can otherwise take both Jardiance and Tradjenta.  Glyxambi is taken along with a good diet and exercise regime.

Glyxambi works multiple ways to lower blood sugar, improve A1C levels, and even may reduce risk of death by cardiovascular disease.  Although, Glyxambi has not been studied in respect to cardiovascular death, empagliflozin, part of Glyxambi, has shown to reduce cardiovascular death.

Glyxambi works by increasing your own insulin production, reducing your own sugar production, and causes more sugar to pass through your urine.  

In clinical studies, 58% of people taking Glyxambi lowered their A1C levels below 7.0.  Also, fasting blood sugar levels were reduced by an average 33 points and an average weight loss of 3% was attained.

Glyxambi is taken once daily in the morning and is the first of this type of combination medicine.

In 2019, when comparing Glyxambi cost to USA Glyxambi coupon price, InsulinHub was found to offer a discount of approximately 60% in Glyxambi savings.

Buy Glyxambi from InsulinHub.com for the best Glyxambi cost.

Information about Glyxambi

Glyxambi is a combination medication that contains two active ingredients: empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. This dual-action formulation is designed to help manage blood sugar levels in adults with type 2 diabetes.

Product Highlights

• Glyxambi is primarily indicated for the treatment of:
• Type 2 diabetes mellitus in adults, particularly when diet and exercise alone do not provide adequate glycemic control.
• It may also be used in combination with other antidiabetic medications.

Key Ingredient

• Empagliflozin
• Linagliptin

Key Benefits

• Aids in lowering HbA1c levels.
• May promote weight loss compared to some other diabetes medications.
• Evidence suggests potential cardiovascular benefits in patients with existing heart conditions.
• Generally has a low risk of causing low blood sugar when used alone.

Direction of Use

• Typically, the recommended dose is one tablet daily, taken with or without food.
• Regular blood glucose monitoring is essential to assess treatment effectiveness.

Safety Concerns

• Common side effects may include urinary tract infections, genital mycotic infections, nausea, and diarrhea.
• Renal function should be monitored regularly, as the medication can affect kidney health.
• There is a risk of ketoacidosis in some patients, which requires immediate medical attention.

Avoid Glyxambi If

• You have a known hypersensitivity to empagliflozin, linagliptin, or any of the excipients in the formulation.
• Not recommended for patients with severe kidney disease (eGFR < 30 mL/min).
• Patients with a history of this condition should avoid Glyxambi.
• Use with caution in combination with certain drugs that can adversely affect renal function or increase the risk of adverse effects.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.